Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Lundbeck is a research-based pharmaceutical company which, since 1989, has concentrated on a single core therapeutic area, namely the development and sale of pharmaceuticals for the treatment of diseases of the central nervous system (CNS). To date, the company has largely focused on drugs for psychiatry and neurology, however it has broader ambitions, namely to become one of the world's leading specialist suppliers of drugs to treat CNS diseases. Future development and growth will be based on the maintenance and expansion of the existing business, streamlining and simplifying, and creating a platform for long-term growth.

Lundbeck expects a consistently positive trend for its new pharmaceuticals in 2007. Lundbeck's four late-stage clinical projects in its development pipeline may have continued development initiatives or potential commercial applications already clarified by the end of 2007. Data is expected in 2007 from the ongoing Phase II trials with Lu AA21004 that will determine how quickly Lundbeck will be able to advance this project towards phase III pivotal trials. Lundbeck also expects to initiate additional studies of pharmaceutical candidates from its in-house research during 2007.

Forest opted to reduce its escitalopram inventories in 2006 from 16 months commercial supply at the end of 2005 to ten months commercial supply at the end of 2006. This extraordinary reduction of Forest's inventories had a significant effect on Lundbeck's financial performance in 2006. This adverse effect was only to a lesser extent balanced out by the positive sales trends for Lexapro in the US markets.